Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-01-04
2011-01-04
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S395000
Reexamination Certificate
active
07863330
ABSTRACT:
Combination of dexloxiglumide and a proton pump inhibitor (PPI) for the treatment of patients suffering from functional dyspepsia and gastroesophageal reflux disease (GERD) is disclosed.
REFERENCES:
patent: 4255431 (1981-03-01), Junggren et al.
patent: 4628098 (1986-12-01), Nohara et al.
patent: 4758579 (1988-07-01), Kohl et al.
patent: 4769389 (1988-09-01), Makovec et al.
patent: 4880938 (1989-11-01), Freidinger
patent: 5045552 (1991-09-01), Souda et al.
patent: 5130474 (1992-07-01), Makovec et al.
patent: 5693818 (1997-12-01), Von Unge
patent: WO 93/12817 (1993-07-01), None
patent: WO 01/85167 (2001-11-01), None
patent: WO 01/85704 (2001-11-01), None
patent: WO 01/85723 (2001-11-01), None
patent: WO 01/85724 (2001-11-01), None
patent: WO 01/90078 (2001-11-01), None
patent: WO 03/041714 (2003-05-01), None
patent: WO 2004/098609 (2004-11-01), None
patent: WO 2004/098610 (2004-11-01), None
patent: WO 2004/101533 (2004-11-01), None
patent: WO 2004/105795 (2004-12-01), None
patent: WO 2005/074931 (2005-08-01), None
Boeckxstaens, G.E.E., Current Treatment Options in Gastroenterology (2001), 4:317-322.
Barclay, L., Drugs in Clinical Trials (Apr. 2005), www.centerwatch.com/professional/cwpipeline/eyeon—gerd.html.
The Merck Index, 17thedition (1999), pp. 221-223.
Persiani et al., Clinical Pharmacokinetics, 45(12), (2006), pp. 1177-1188 (abstract).
Holstein et al., MI1437, AZD0865—A New Potassium-Competitive Acid Blocker—Exhibits Maximal Gastric Antisecretory Effects from First Dose, AGA Abstracts, p. A-333.
Borovicka et al., “Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans”, Am. J. Physiol. 271 (Gastrointest. Liver Physiol . 34): G448-G453, 1996.
Chua et al., “Cholecystokinin Hyperresponsiveness in Dysmotility-Type Nonulcer Dyspepsia”; pp. 298-299.
Chua et al., “Clinical Efficacy and Prokinetic Effect of the CCK-A Antagonist Loxiglumide in Nonulcer Dyspepsia”, Cholecystokinin, Annals of the New York Academy of Sciences, Mar. 23, 1994, vol. 713, pp. 451-453.
Feinle et al., “Cholecystokinin-A Receptors Modulate Gastric Sensory and Motor Responses to Gastric Distention and Duodenal Lipid”, Gastroenterology 1996, vol. 110, pp. 1379-1385.
Feinle et al., “Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia”, Gut 2001, vol. 48, pp. 347-355.
Katschinski et al., “Intestinal phase of human antro-pyloro-duodenal motility: cholinergic and CCK-mediated regulation”, European Journal of Clinical Investigation (1996), vol. 26, pp. 574-583.
Lal et al., “Cholecystokinin pathways modulate sensations induced by gastric distension in humans”; Am. J. Physiol. Gastrointest Liver Physiol. 287; pp. G72-G79; 2004.
Lassen et al., “Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial”, The Lancet, vol. 356, Aug. 5, 2000, pp. 455-460.
Locke et al., “Prevalence and Clinical Spectrum of Gastroesophageal Reflux: A Population-Based Study in Olmsted County, Minnesota”, Gastroenterology 1997; vol. 112, pp. 1448-1456.
Schwizer et al., “Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide”, Gut 1997, vol. 41, pp. 500-504.
Tougas et al., “Prevalence and Impact of Upper Gastrointestinal Symptoms in the Canadian Population: Findings From the Digest Study”, The American Journal of Gastroenterology, vol. 94, No. 10, 1999, pp. 2845-2854.
Woodruff et al., “Cholecystokinin Antagonists”, Annu. Rev. Pharmacol. Toxicol. 1991, vol. 31, pp. 469-501.
Remington's 18th Edition, Pharmaceutical Sciences, 1990, pp. 1449-1450.
Noble et al., “International Union of Pharmacology, XXL. Structure, Distribution, and Functions of Cholecystokinin Receptors”, Pharmacological Reviews, vol. 51, No. 4, pp. 745-781.
D'Amato et al., “Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders”, Exp. Opin. Invest. Drugs (1997), 6(7):819-836.
Crawley et al., “Biological Actions of Cholecystokinin”, Peptides, vol. 15, No. 4, pp. 731-755, 1994.
Tonini et al., “Progress with Novel Pharmacological Strategies for Gastro-oesophageal Reflux Disease”, Drugs 2004; 64(4); 347-361.
Varga, Dexloxiglumide Rotta Research Lab, Investigational Drugs 2002, 3(4):621-626.
Scarpignato et al., Effect of CCK and its antagonists on gastric emptying, J. Physiology (1993), vol. 87, pp. 291-300.
Russo et al., Digestive and Liver Diseases Statistics, 2004, Gastroenterology 2004; vol. 126, pp. 1448-1453.
Dent et al., “Sympton evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs”, Gut 2004; vol. 53, pp. 1-24.
D'Amato Massimo Maria
Giordani Antonio
Makovec Francesco
Rovati Lucio Claudio
Rottapharm S.p.A.
Spivack Phyllis G.
Sughrue & Mion, PLLC
LandOfFree
Deloxiglumide and proton pump inhibitor combination in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Deloxiglumide and proton pump inhibitor combination in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Deloxiglumide and proton pump inhibitor combination in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2672562